Amneal appoints Gustavo Pesquin as EVP, Chief Commercial Officer – Specialty

Amneal Pharmaceuticals, Inc.

Pesquin joins from Sanofi, where he was North America Head for General Medicines.
Base salary $525,000; target annual bonus 60% of base salary; RSU grant of $1,000,000 vesting over 4 years.
Severance: 150% of base salary plus pro-rata bonus and 18 months benefits if terminated without cause or for good reason.
Effective September 6, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gustavo J. Pesquin

Executive Vice President and Chief Commercial Officer – Specialty

AMRX · Amneal Pharmaceuticals, Inc.

Effective: 2022-09-06
Filed: September 6, 2022, 7:59 PM ET

On September 1, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Gustavo J. Pesquin as the Company’s Executive Vice President and Chief Commercial Officer – Specialty, effective September 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Gustavo J. Pesquin was appointed as Executive Vice President and Chief Commercial Officer – Specialty at Amneal Pharmaceuticals, Inc..

Action: appointed
Role: Executive Vice President and Chief Commercial Officer – Specialty

Exact text from the filing

On September 1, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Gustavo J. Pesquin as the Company’s Executive Vice President and Chief Commercial Officer – Specialty, effective September 6, 2022.

View on SEC.gov

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-238857

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.